Treatment Options in the Frontline Setting for Metastatic HER2+ Breast Cancer

The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

A multidisciplinary care approach should be utilized when discussing sexual health with survivors of breast cancer.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Breast MRI in patients with newly diagnosed breast cancer increased mastectomy rates and biopsy needs.

Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.